Beyond ipilimumab: new approaches target the immunological synapse

J Natl Cancer Inst. 2011 Jul 20;103(14):1079-82. doi: 10.1093/jnci/djr281. Epub 2011 Jul 7.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Antigens, CD / drug effects
  • Antigens, CD / immunology
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Apoptosis Regulatory Proteins / drug effects
  • Apoptosis Regulatory Proteins / immunology
  • CD40 Antigens / drug effects
  • CD40 Antigens / immunology
  • Clinical Trials, Phase III as Topic
  • Drug Approval
  • Glucocorticoid-Induced TNFR-Related Protein / drug effects
  • Glucocorticoid-Induced TNFR-Related Protein / immunology
  • Humans
  • Immunological Synapses / drug effects*
  • Immunotherapy / methods*
  • Ipilimumab
  • Lymphocyte Activation / drug effects
  • Melanoma / drug therapy
  • Melanoma / immunology
  • Neoplasms / drug therapy*
  • Neoplasms / immunology*
  • Nivolumab
  • OX40 Ligand / drug effects
  • OX40 Ligand / immunology
  • Programmed Cell Death 1 Receptor
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / immunology
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology*

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • CD40 Antigens
  • Glucocorticoid-Induced TNFR-Related Protein
  • Ipilimumab
  • OX40 Ligand
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • TNFRSF18 protein, human
  • TNFSF4 protein, human
  • Nivolumab